Tevogen Bio's (TVGN) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Tevogen Bio (NASDAQ:TVGN) received a reiterated "sell (E+)" rating from Weiss Ratings, indicating a negative outlook for the stock.
• Despite the "sell" rating from Weiss, D. Boral Capital reiterated a "buy" rating with a target price of $10.00, reflecting mixed analyst sentiment.
• The company's stock closed at $0.72 with a market cap of $142.40 million, and it has experienced a 52-week low of $0.26 and a high of $3.09.

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "sell (e+)" rating reiterated by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, D. Boral Capital reiterated a "buy" rating and set a $10.00 target price on shares of Tevogen Bio in a research note on Thursday, September 4th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $10.00.

Tevogen Bio Price Performance

NASDAQ TVGN traded down $0.02 during trading on Wednesday, reaching $0.72. 314,095 shares of the company's stock were exchanged, compared to its average volume of 560,956. The business has a 50 day moving average price of $0.87 and a 200-day moving average price of $1.05. The stock has a market capitalization of $142.40 million, a P/E ratio of -3.81 and a beta of -0.83. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $3.09.

Tevogen Bio (NASDAQ:TVGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 19th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02.

Institutional Investors Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. Nuveen LLC purchased a new stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 90,253 shares of the company's stock, valued at approximately $97,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.